Prior approval / documentation note

Prior approval: Not applicable for this policy, but when prior authorization is required by the payer, submit full medical records as described below. Documentation should clearly reference the specific intended augmentation procedure and device/implant to be used.

• If prior authorization is required by Blue Cross Blue Shield - Iowa follow payer-specific submission process and include all items listed under Required Documentation.

Device clearance documentation

Document the specific device or implant to be used and include evidence of FDA clearance (eg, 510(k) number) when applicable. For marketed devices (balloon tamps, mechanical augmentation systems, expandable implants, proprietary cements), include device name, manufacturer, and clearance documentation.

• List the device/implant trade name, manufacturer, and 510(k) number or other FDA marketing clearance information where available (eg, KyphX® inflatable bone tamp Kxxxxxx; StabiliT® Vertebral Augmentation System).
• If an investigational or non–FDA-cleared device is proposed, note that coverage may be denied as investigational.

Prior authorization: imaging and conservative therapy documentation

For prior authorization, provide imaging confirmation of the fracture (preferably MRI demonstrating bone marrow edema or correlating acute/subacute change) and documentation of failed conservative therapy where required by indication.

• Attach completed reports of diagnostic imaging (MRI, CT, radiographs) localizing the treated level(s) and showing fracture age and characteristics.
• Document conservative care attempted (medication trials, bracing, physical therapy) including start/end dates and response.

Prior authorization: specify technique and conservative care status

Specify the exact vertebral augmentation technique proposed (vertebroplasty, balloon kyphoplasty, radiofrequency-targeted augmentation, Kiva, SpineJack, sacroplasty) and clearly state whether conservative care has been tried and failed or the reason conservative care is being bypassed (eg, nonambulatory due to pain, hospitalization).

• Include operative plan describing approach, levels, laterality, type of cement/injectate, and use of balloons, implants, or mechanical devices.
• If conservative care is being exempted (eg, <6 weeks with hospitalization or inability to ambulate), provide documentation to support exemption.

Prior authorization: clinical criteria referenced

When prior authorization decisions reference trial-based clinical criteria, include objective baseline measures and threshold values used in trials (eg, pain scores, ODI/RMDQ) to support medical necessity.

• Provide baseline pain score (VAS/NRS) and functional measures (Oswestry Disability Index, Roland-Morris Disability Questionnaire) with dates.
• Note duration of symptoms and timeframe of conservative care relative to trial entry criteria (eg, ≥6 weeks of conservative therapy for many RCT inclusion criteria).

Prior conservative care and surgical candidacy

Prior conservative care is generally required before augmentation unless the patient meets surgical candidacy exemptions (eg, severe pain preventing ambulation or hospitalization). Document failure or intolerance of conservative therapy and assess surgical candidacy consistent with society guidance.

• Document trial of optimal conservative therapy (see Conservative Therapy) including analgesics, bracing, and provider-directed exercise for >6 weeks when applicable.
• When claiming surgical candidacy, provide clinical notes describing functional limitations, inability to participate in PT, or unacceptable analgesic side effects.

Prior authorization: show failed conservative therapy and imaging

For prior authorization, include a clear statement demonstrating failure of conservative therapy and attach correlated imaging that confirms the treated fracture(s). Imaging should support fracture acuity when required (eg, MRI bone marrow edema for fractures between 6 weeks and 1 year).

• Attach imaging demonstrating level(s) to be treated and report dates; MRI is preferred to corroborate acuity/subacute changes.
• Include treatment timeline showing conservative measures tried and objective evidence of persistent, debilitating pain despite those measures.

Prior authorization and code list

Follow payer-specific prior authorization processes and ensure coding matches the performed procedure. Use the CPT and Category III codes listed in the policy when submitting authorization and claims.

• Submit appropriate CPT codes such as 22510–22515 (vertebroplasty/augmentation) and unlisted spine 22899 when applicable.
• For sacroplasty use Category III codes 0200T/0201T and reference associated HCPCS mappings (C1062, C7504–C7508) per policy tables.

Denial triggers

Denial triggers include lack of documentation meeting the medical necessity criteria, procedures performed outside the covered indications (eg, cervical spine, thoracic T1–T4, prophylactic use), or use of techniques/devices considered investigational.

• Claims may be denied if records do not document failed conservative therapy when required, or if imaging does not confirm the symptomatic fracture at the treated level.
• Procedures for noncovered indications (eg, prophylactic augmentation, nonpainful hemangiomas, sacroplasty for sacral lesions when considered investigational by this policy) risk denial.

Safety-related denial risk

Safety-related denial risk: cement or injectate leakage and device-related complications are principal safety concerns. Insufficient documentation of risk mitigation, informed consent, or absence of contraindications may prompt additional review or denial.

• Document assessment and plan to minimize cement extravasation and management plans for potential complications.
• Report any prior adverse events or anatomical factors increasing risk of leakage; lack of such documentation may lead to scrutiny.

High crossover, lack of blinding, or failed trial limitations

Evidence limitations: RCTs with high crossover, lack of blinding in some trials, and methodological heterogeneity complicate interpretation of benefit. When relying on such evidence, provide clear rationale and individualized documentation of expected benefit.

• Trials with substantial crossover (eg, control-to-procedure crossover rates) weaken intention-to-treat analyses — document why the patient differs from trial populations if using observational evidence to justify treatment.
• Be explicit about why sham-controlled trial limitations (eg, unblinding due to anesthetic effects) do not preclude benefit for this patient.

Evidence base for sacroplasty lacks randomized trials

Sacroplasty evidence lacks randomized trials and is based primarily on observational series with small numbers and methodological limitations. Justify use of sacroplasty by documenting failure or insufficiency of conservative management and the clinical rationale for intervention.

• Provide detailed clinical history, pain scores, functional impairment, prior conservative measures and duration, and rationale for choosing sacroplasty despite limited RCT evidence.
• Note potential higher uncertainty regarding long-term harms given limited sample sizes in published series.

Studies with duplicative or overlapping populations

Avoid using studies with duplicative or overlapping populations to justify coverage. Ensure referenced literature and registries represent independent cohorts and document how the patient's presentation aligns with nonoverlapping study populations.

• If citing institutional series or registries, disclose overlap with prior published cohorts and provide independent supporting data when possible.

Procedure and material documentation

Procedure and material documentation: include planned materials (type/brand of cement or injectate), volume estimates, and any adjunctive devices (balloon, implant, tamp). Operative consent and device-specific training or credentialing details may be requested.

• Specify cement type (eg, PMMA, proprietary formulations), expected volume, and whether biopsy is planned.
• Include documentation of operator credentialing or institutional privileging for device-specific techniques if available.

Required clinical documentation

Required clinical documentation: the submission should include diagnosis, onset and duration of symptoms, baseline pain and functional scores, prior conservative care with dates, imaging reports, and absence of alternative causes of pain (eg, spinal canal compression).

• Document that the pain is localized to the treated level and that other causes (eg, disk herniation or spinal stenosis) have been ruled out by CT or MRI.
• Include note on vertebral body integrity (eg, at least one-third of original height remaining) when applicable to eligibility criteria.

Providers should document fracture confirmation

Providers should document fracture confirmation (preferably MRI demonstrating bone marrow edema or intravertebral cleft for symptomatic fractures), pain duration, and correlation between imaging and clinical exam.

• For fractures between 6 weeks and 1 year, include imaging demonstrating subacute changes (bone marrow edema) and clinical notes correlating pain to that level.
• For acute fractures (<6 weeks) that bypass conservative care requirement due to hospitalization or inability to ambulate, include supporting hospital records.

Document symptomatic osteoporotic vertebral compression fractures

Document symptomatic osteoporotic vertebral compression fractures with objective measures of pain and functional impairment and show that conservative care was attempted and failed when required by criteria.

• Include VAS/NRS pain scores and functional indices (ODI, RMDQ) with dates to demonstrate severity and refractory nature of symptoms.

Clinical documentation should include diagnosis and follow-up measures

Clinical documentation should include diagnosis, baseline pain/function measures, prior conservative care and response, imaging/lab support when applicable, and any contraindications to conservative therapy.

• When treating metastatic or neoplastic lesions, document oncologic treatment plan and timing of radiotherapy/chemotherapy relative to proposed augmentation.

Documentation to support medical necessity

Documentation to support medical necessity may reference trial inclusion thresholds (eg, minimum pain scores, ODI thresholds) but must be individualized. Provide objective pre-procedure measures and planned postprocedure follow-up assessments.

• Supply baseline and planned follow-up assessment schedule (eg, VAS and ODI at 1 month, 6 months, 12 months) to allow outcome tracking.
• If using device-specific trials to justify coverage, demonstrate how the patient meets the trial entry criteria.

Document prior conservative management and imaging follow-up

Document prior conservative management and imaging follow-up consistent with trial protocols when applicable. Records should show duration, type, and adequacy of conservative therapy before considering augmentation.

• Conservative therapy examples: prescription-strength analgesics/steroids/NSAIDs, bracing, and a provider-directed exercise program for >6 weeks unless exempted.
• If conservative therapy was intolerable or contraindicated, provide documentation of adverse effects or clinical inability to participate.

Documentation should demonstrate failure of conservative therapy

Documentation should demonstrate failure of conservative therapy using explicit definitions where available (eg, Society of Interventional Radiology failure definitions) or show clinical circumstances meeting exemption criteria (eg, nonambulatory after 24 hours of analgesia).

• Use clear timelines and objective evidence (progress notes, pain scores, functional declines) to demonstrate refractoriness to conservative care.
• If applying SIR failure definitions, include documentation of attempts at analgesia and the resulting level of functioning or intolerance.

Conservative therapy requirement

Conservative therapy requirement: optimal conservative therapy (analgesics, bracing, and provider-directed exercise) is generally required for a minimum of 6 weeks for symptomatic osteoporotic or steroid-induced fractures unless specific exemption criteria are met.

• Document dates and specifics of conservative measures; absence of adequate conservative therapy without documented exemption may lead to denial.

Conservative therapy first

Conservative therapy first: conservative management is appropriate as first-line care for many fracture types and for metastatic lesions where radiotherapy/chemotherapy are expected to address symptoms; document rationale if augmentation is selected earlier.

• When augmentation is performed prior to expected effect of oncologic therapies, document rationale (eg, imminent risk of collapse, refractory pain despite initial cancer-directed therapy).

Evidence from nonblinded and blinded RCTs

Evidence from nonblinded and blinded RCTs is mixed; when relying on trial data to support treatment, acknowledge methodological limitations (heterogeneity, underpowered outcomes) and provide individualized justification.

• Cite relevant trial criteria and explain how the patient's clinical picture aligns with favorable trial subgroups if applicable.

Conservative management is the primary comparator

Conservative management is the primary comparator in trials and should be documented as the comparator attempted prior to augmentation when appropriate.

• List conservative modalities tried (PT, analgesics, bracing, bed rest) and outcomes for each modality.

Conservative care (bed rest, analgesia, bracing, exercise)

Conservative care examples to document include bed rest, analgesia, bracing, and provider-directed exercise programs. Record duration and response for each modality.

• Specify medication names/doses, brace type and wear schedule, and PT session dates and objectives.

Step therapy: conservative care precedes augmentation in trials

Step therapy: in many trials, conservative care preceded augmentation, implying an operational step-therapy approach. Prior authorization should reflect that conservative care was attempted per the policy unless an exemption is documented.

• If requesting an exception to step therapy, include documentation supporting exemption criteria (eg, hospitalized due to fracture-related pain).

Prior conservative therapy

Prior conservative therapy: reiterate and document prior conservative care attempts and outcomes before approval of augmentation procedures unless clear exemption criteria apply.

• Include dates, response, and reasons for discontinuation of prior conservative therapies.

Comparators of interest include conservative management

Comparators of interest include conservative management modalities; when using observational evidence showing benefit over conservative care, document distinctions between the study population and the individual patient.

• Explain why the patient is expected to derive benefit relative to conservative management given their specific clinical features.

Consideration of conservative management

Consideration of conservative management: multiple specialty societies recommend considering conservative care prior to augmentation; document adherence to or justified deviation from society recommendations.

• If deviating from society guidance, provide detailed clinical justification in the chart.